Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism

DOI Web Site PubMed Open Access
  • Chikugo Momoko
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University
  • Sebe Mayu
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University
  • Tsutsumi Rie
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University
  • Iuchi Marina
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University
  • Kishi Jun
    Department of Respiratory Medicine and Rheumatology, Institute of Biomedical Sciences, Tokushima University
  • Kuroda Masashi
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University
  • Harada Nagakatsu
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University
  • Nishioka Yasuhiko
    Department of Respiratory Medicine and Rheumatology, Institute of Biomedical Sciences, Tokushima University
  • Sakaue Hiroshi
    Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University

Search this article

Abstract

<p>Tofacitinib is the first Janus Kinase (JAK) inhibitor to treat moderately to severely active RA. In this study, we investigated whether the effect of tofacitinib have any effects on body composition in mice and female patients with RA. Female C57BL/6 mice fed with a high‐fat diet were treated with 30 mg/kg/day tofacitinib or vehicle for 70 days. Following treatment, trunk muscle, subcutaneous fat, and visceral fats were measured using X‐ray computed tomography CT scan. Glucose tolerance and insulin sensitivity were assessed. In female RA patients treated with biological disease modified anti‐rheumatic‐drugs (biological DMARDs) or tofacitinib (n=4 per group), we also evaluated the body composition after 3 months from the start of treatment initiation using bioelectrical impedance analysis. Treatment with tofacitinib did not affect the body weight, and body composition in C57BL/6 mice. It also did not affect glucose, and insulin tolerance in mice. In patients with RA, treatment with biological DMARDs did not affect the body composition whereas the muscle mass was unchanged after receiving tofacitinib and the fat mass was significantly increased. J. Med. Invest. 65:166‐170, August, 2018</p>

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top